Merck Matches Sandoz With Canadian Etanercept Indications
Brenzys Biosimilar To Enbrel Gets Further Indications Already Enjoyed By Erelzi
Merck, Sharp & Dohme’s Brenzys biosimilar version of Amgen’s Enbrel has received four new indications in Canada, bringing it in line with Sandoz’ rival biosimilar, Erelzi.
You may also be interested in...
Sandoz Canada is continuing to expand its biosimilars footprint with entry into oncology, while also broadening its presence for autoimmune disorders like rheumatoid arthritis.
Speaking with Generics Bulletin as Sandoz Canada unveiled its landmark public education campaign, The Biosimilars Generation, Karine Matteau, the company’s biosimilars leader, talked about how it plans to remain a leader in the biosimilars field as well as the company’s response to the COVID-19 pandemic.
A dedicated website will spearhead a public education campaign initiated by Sandoz Canada for biosimilars, as their influence and presence continue to grow in the North American market. Sandoz itself is planning a portfolio of five products by the middle of 2021.